GTCR Acquires Zentiva from Advent

Zentiva Completes Voluntary Public Purchase Offer for APONTIS PHARMA AG

December 9, 2024

Pharmaceuticals

Zentiva has completed its voluntary public purchase offer for the shares of APONTIS PHARMA AG. Following settlement, Zentiva holds approximately 83.57% of the share capital and approximately 85.27% of the voting rights, with management agreeing to terminate the shares’ inclusion in trading on the Freiverkehr immediately after settlement.

GTCR Invests $1.33 Billion in Tricentis

November 26, 2024

Software

GTCR has signed a definitive agreement to invest $1.33 billion in Tricentis, valuing the enterprise at $4.5 billion. Insight Partners will continue as a significant investor and will work with GTCR with equal board representation as Tricentis uses the capital to fuel growth, product innovation, and global expansion.

Zevra Therapeutics Acquires Acer Therapeutics

November 20, 2023

Pharmaceuticals

Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.

AstraZeneca Acquires Neogene Therapeutics

November 29, 2022

Biotechnology

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.

Grünenthal Acquires Kyowa Kirin’s 49% Stake in Grünenthal Meds JV

March 2, 2026

Pharmaceuticals

Grünenthal acquired Kyowa Kirin International’s 49% stake in Grünenthal Meds, taking full ownership of the joint venture created in 2023 to market Grünenthal’s established medicines portfolio. The JV manages a portfolio of 12 established brands across six therapeutic areas and more than 60 markets, with key products including Abstral, PecFent, Moventig, and Adcal-D3.

EQT X to Acquire Adalvo (B2B Generic Drug Dossiers)

July 18, 2025

Healthcare Services

EQT X (EQT) has agreed to acquire a majority stake in Adalvo, an asset-light B2B dossier developer that produces market-approval-ready generic drug dossiers for pharmaceutical companies. Existing shareholders, including Aztiq (holding company of Chairman Róbert Wessman), will reinvest part of their holdings and retain minority ownership. The deal is subject to customary approvals and is expected to close in H2 2025.